BioSpace News Archive

Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2021.

Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.

With the ongoing global pandemic, BioNTech and Pfizer announced that they will be boosting their manufacturing capacity of the COVID-19 vaccine to 2.5 billion for 2021.

Disappointing data from two Phase Ib/IIa trials for both lead Huntington’s disease antisense candidates have pushed Wave Life Sciences to shelve the assets and focus on its next generation of therapies.

MediXall Group, Inc., a healthcare solutions provider, is pleased to announce that its subsidiary, Health Karma, is signing up customers nationwide through all current sales and marketing channels.

Mar. 30, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that European Medicines Agency (EMA) has granted orphan drug designation to JR-171, an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome).

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from No

Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer

Alvalux Medical, a Belgian medtech wearables company, and its USA subsidiary CicaLux Inc., has been awarded its first patent from the United States Patent and Trademark Office for its CicaLux ® product line.